Ye Liu

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

Yunhang Guo, Ye Liu, Nan Hu et al. · Journal of Medicinal Chemistry · 2019 · 332 citations · Full text

IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma

Erik Ladomersky, Lijie Zhai, Alicia Lenzen et al. · Clinical Cancer Research · 2018 · 202 citations · Full text

Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor

Yao Xiong, Yin Guo, Ye Liu et al. · Neoplasia · 2020 · 95 citations · Full text

Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study

Mazyar Shadman, Ian W. Flinn, Moshe Levy et al. · The Lancet Haematology · 2022 · 81 citations

Single-arm Study, Oncology, Medicine +9

Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage

Hong Yuan, Yingcai Feng, Hanzi Sun et al. · FEBS Open Bio · 2021 · 70 citations · Full text

Immunology, Cc′ Loop, Molecular Biology +16